Role of biomarkers in diagnostics, stratification of risk and prognosis of heart failure.


  • О. О. Khanyukov
  • L. V. Sapozhnychenko



heart failure, biomarkers, diagnostics, prognosis


Heart failure occupies one of the leading places in the structure of the causes of adult mortality in the world. The issues of timely diagnosis and prognosis of the outcomes of this disease do not lose their relevance due to the high heterogeneity of clinical manifestations and absence of absolutely pathognomonic symptoms. The development of the multimarker diagnostic strategy for management of patients with heart failure is a progressive approach .The review focuses on the synthesis of known evidence data on the role of biomarkers in diagnostics and risk stratification.

Author Biographies

О. О. Khanyukov

SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»
Department of Internal Medicine 3
V. Vernadsky str., 9, Dnipro, 49044, Ukraine

L. V. Sapozhnychenko

SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»
Department of Internal Medicine 3
V. Vernadsky str., 9, Dnipro, 49044, Ukraine


Kuryata OV, Kushnir YuS. Chronic Heart Failure with Preserved Systolic Function: the Features of Morpho­logical and Functional Status of Platelets and Their Changes under the Influence of the Influence of the Treatment. Emergency Medicine. 2013;6(53):113-118.

Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Up­date of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology. American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society ofAme­rica. J Card Fail; 2017. doi: 10.1016/j.cardfail.2017.04.014

Kociol R, Horton J, Fonarow G, et al. Admission, Discharge, or Change in B-Type Natriuretic Peptide and Long-Term Outcomes: Data From Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF) Linked to Medicare Claims. Circulation: Heart Failure. 2011;4(5):628-36. doi: 10.1161/ circheartfailure.111.962290

Kaypakli O1, Gür M2, Gözükara MY3, Uçar H2, Kivrak A2, Şeker T2, Şahin DY2, Elbasan Z2, Türkoğlu C2, Çayli M2. Association between high-sensitivity tro­ponin T, left ventricular hypertrophy, and myocardial performance index. Herz. 2015 Nov;40(7):1004-10. doi: 10.1007/s00059-015-4322-3. Epub 2015 Jun 19.

Lopez-Andrès N1, Rossignol P, Iraqi W, Fay R, Nuée J, Ghio S, Cleland JG, Zannad F, Lacolley P. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.Eur J Heart Fail. 2012 Jan;14(1):74-81. doi: 10.1093/eurjhf/hfr151. Epub 2011 Nov 16.

Savarese G, Musella F, D'Amore C, Vassallo E, Losco T, Gambardella F, Cecere M, Petraglia L, Paga­no G, Fimiani L, Rengo G, Leosco D, Trimarco B, Per­rone-Filardi P. Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis.JACC Heart Fail. 2014 Apr;2(2):148-58. doi: 10.1016/j.jchf.2013.11.007

de Antonio M, Lupon J, Galan A, et al. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure. American Heart Journal. 2012;163(5):821-8. doi: 10.1016/j.ahj.2012.03.004

Josep Lupo´n, Marta de Antonio, Joan Vila, Judith Pen˜afiel, Amparo Gala´n, Elisabet Zamora, Agustı´n Urrutia, Antoni Bayes-Genis. Developmentof a Novel Heart Failure Risk Tool: The Barcelona Bio-Heart Failure Risk Calculator (BCN Bio-HFCalculator) PLOS ONE January 2014;9(1):e85466.

de Denus S1, Lavoie J, Ducharme A, O'Meara E, Racine N, Sirois MG, Neagoe PE, Zhu L, Rouleau JL, White M. Differences in biomarkers in patients with heart failure with a reduced vs a preserved left ventricular ejection fraction. Can J Cardiol. 2012 Jan-Feb;28(1):62-8. doi: 10.1016/j.cjca.2011.09.007. Epub 2011 Nov 21.

Doust J. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ. 2005;330(7492):625-0. doi: 10.1136/ bmj.330.7492.625

Klersy C, Silvestri AD, Gabutti G, et al. Eco­nomic impact of remote patient monitoring: an integrated economic model derived from a meta-analysis of ran­domized controlled trials in heart failure. Eur J Heart Fail. 2011;13(12);450-9.

Ponikowski P, Voors AA,AnkerSD, et al. Authors / Task Force Members. 2016 ESC guide lines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heartfailure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) ofthe ESC. EurHeart J. 2016;37:129-2200.

Lok D, Lok S, Bruggink-André de la Porte P, et al. Galectin-3 is an independent marker for ventricular re­modeling and mortality in patients with chronic heart failure. Clin Res Cardiol. 2012;102(2):103-10. doi: 10.1007/s00392-012-0500-y

Baessler A, Strack C, Rousseva E, et al. Growth-differentiation factor-15 improves reclassification for the diagnosis of heart failure with normal ejection fraction in morbid obesity. European Journal of Heart Failure. 2012;14(11):1240-8. doi: 10.1093/eurjhf/ hfs116

Uçar H, Gür M, Kivrak A, Koyunsever NY, Se­ker T, Akilli RE, Türkoğlu C, Kaypakli O, Sahin DY, El­basan Z, Tanboğa Hİ, Cayli M. High-sensitivity cardiac troponin T levels in newly diagnosed hypertensive pa­tients with different left ventricle geometry. Blood Press. 2014 Aug;23(4):240-7. doi: 10.3109/08037051.2013.840429. Epub 2013 Sep 23.

Kempf T, Wollert K. Growth-Differentiation Fac­tor-15 inHeart Failure. Heart Failure Clinics. 2009;5(4):537-47. doi: 10.1016/j.hfc.2009.04.006

Lok SI, Nous FM, vanKuik J. Myocardial fibrosis and pro-fibrotic markers in end-stage heart failure patients during continuous-flow left ventricular assist device support. Eur J CardiothoracSurg. 2015 Sep;48(3):407-15.

Masson S1, Latini R.Amino-terminal pro-B-type natriuretic peptides and prognosis in chronic heart failure. Am J Cardiol. 2008 Feb 4;101(3A):56-60. doi: 10.1016/j.amjcard.2007.11.024

Michael Felker G, Fiuzat M, Thompson V. So­luble ST2 in Ambulatory Patients With Heart Failure Association With Functional Capacity and Long-Term Outcomes. 2013;6:1172-9.

Cohen-Solal A, Logeart D, Huang B, et al. Lo­wered B-Type Natriuretic Peptide in Response to Le­vosimendan or Dobutamine Treatment Is Associated With Improved Survival in Patients With Severe Acutely Decompensated Heart Failure. Journal of theAmericanCollegeof Cardiology. 2009;53(25):2343-8. doi: 10.1016/j.jacc.2009.02.058

D’Alessandro R, Masarone D, Buono A, et al. Natriuretic peptides: molecular biology, pathophysiology and clinical implications for the cardiologist. Future Cardiology. 2013;9(4):519-34.

Savarese G, Trimarco B, Dellegrottaglie S, Pras­taro M, Gambardella F, Rengo G, Leosco D, Perrone-Fi­lardi P. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. PLoS One. 2013;8(3):e58287. doi: 10.1371/journal.pone.0058287. Epub 2013 Mar 5.

van der Velde A, Gullestad L, Ueland T, et al. Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients With Heart Failure: Data From CORONA and COACH. Circulation: HeartFailure. 2013;6(2):219-26. doi: 10.1161/circheartfailure.112.000129

Miller W, Hartman K, Grill D, et al. Serial mea­surements of mid region proANP and copeptin in ambulatory patients with heart failure: incremental prog­nostic value of novel biomarkers in heart failure. Heart. 2011;98(5):389-94. doi: 10.1136/heartjnl-2011-300823

Masson S, Anand I, Favero C, et al. Serial Mea­surement of Cardiac Troponin T Using a Highly Sensitive Assay in Patients With Chronic Heart Failure: Data From 2 Large Randomized Clinical Trials. Circulation. 2011;125(2):280-8. doi: 10.1161/circulatio­naha.111.044149

Smith K, deFilippi C, Isakova T, Gutiérrez OM, Laliberte K, Seliger S, Kelley W, Duh SH, Hise M, Christenson R, Wolf M, Januzzi J. Fibroblast growth fac­tor 23, high-sensitivity cardiactroponin, and left ven­tricular hypertrophyin CKD. Am J KidneyDis. 2013 Jan;61(1):67-73. doi: 10.1053/j.ajkd.2012.06.022. Epub 2012 Aug 9.

Bayes-Genis A, Pascual-Figal D, Januzzi J, et al. Soluble ST2 Monitoring Provides Additional Risk Stra­tification for Outpatients With Decompensated Heart Fai­lure. RevistaEspañoladeCardiología (EnglishEdition). 2010;63(10):1171-8. doi: 10.1016/s1885- 5857(10)70231-0

Stephen J Greene, Adrian F Hernandez, Jie-Lena Sun. Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points / Cir­culation: Heart Failure. 2016;9.

Stahrenberg R, Edelmann F, Mende M, et al. The novel biomarker growth differentiation factor15 inheart failure with normal ejection fraction. European Journal of Heart Failure. 2010;12(12):1309-16. doi: 10.1093/eurjhf/hfq151

Wayne C Levy, Dariush Mozaffarian, David T Linker, Santosh C Sutradhar, Stefan D Anker, Anne B Cropp, Inder Anand, Aldo Maggioni, Paul Burton, Mark D Sullivan, Bertram Pitt, Philip A Poole-Wilson, Douglas L Mann, Milton Packer. TheSeattleHeart Failure Model Prediction of Survivalin Heart Failure Circulation. 2006;113:1424-33.

Bailey AM, Arcidiacono J,BentonKA, Tara­pore­wala Z, Winitsky S. United States Food and Drug Admini­stration Regulation of Geneand Cell Therapies. Adv Exp Med Biol. 2015;871:1-29. doi: 10.1007/978-3-319-18618-4_1

Kempf T, Eden M, Strelau J, et al. The transfo­rming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ische­mia/reperfusion injury. Circ Res 2006;98:351-60.

How to Cite

Khanyukov ОО, Sapozhnychenko LV. Role of biomarkers in diagnostics, stratification of risk and prognosis of heart failure. Med. perspekt. [Internet]. 2018May24 [cited 2021May12];23(2(part1):56-63. Available from:




Most read articles by the same author(s)